High-Throughput Drug Discovery for a Rare Neurological Disorder: Uncovering a Novel Therapeutic Opportunity for the 19q12 Autism Spectrum Disorder [post treatment entrectinib patient data]
RNA-seq (gene expression) · human · 10 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 10 samples: 3 × Patient pre-treatment vs 3 × Patient 3 months post treatment vs 3 × Patient 6 months post treatmentGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- High-throughput transcriptomic screening reveals entrectinib as a repositioning opportunity in 19q12 autism spectrum disorderScientific reports · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE292760_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1241207 and SRA study SRP572640. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 9 samples read as cases, 1 as controls.
How we read this: 3 replicated groups read from 10 sample titles; they account for 9 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8864837 Patient pre-treatment biological replicate 1 Patient pre-treatment
- GSM8864838 Patient pre-treatment biological replicate 2 Patient pre-treatment
- GSM8864839 Patient pre-treatment biological replicate 3 Patient pre-treatment
- GSM8864840 Patient 3 months post treatment biological replicate 1 Patient 3 months post t…
- GSM8864841 Patient 3 months post treatment biological replicate 2 Patient 3 months post t…
- GSM8864842 Patient 3 months post treatment biological replicate 3 Patient 3 months post t…
- GSM8864843 Patient 6 months post treatment biological replicate 1 Patient 6 months post t…
- GSM8864844 Patient 6 months post treatment biological replicate 2 Patient 6 months post t…
- GSM8864845 Patient 6 months post treatment biological replicate 3 Patient 6 months post t…
- GSM8864846 Sibling control
- GSE300385 Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies 12 samples shares therapeutic, discovery
- GSE291301 DNA demethylating agents represent a therapeutic opportunity for synovial sarcoma [RNA-Seq] 10 samples shares therapeutic, opportunity
- GSE271332 High-Throughput Transcriptomics Toxicity Assessment of Eleven Data-Poor Bisphenol A Alternatives 286 samples shares high-throughput
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples shares therapeutic
- GSE215274 Identification of Whole Blood Gene Expression Signature to Predict the Therapeutic Effect of Nintedanib in Idiopathic Pulmonary Fibrosis 177 samples shares therapeutic
- GSE255889 Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product 110 samples shares high-throughput
- GSE275870 Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities 108 samples shares therapeutic
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares therapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.